Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 27, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification of share transactions rather than a financial performance report.
Material Changes
The filing details a specific transaction on September 26, 2005, where Abacus (GSK) Trustees Limited, acting as trustee for the GlaxoSmithKline Employee Trust ("the GSK Trust"), transferred 32,688 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. The Company was advised of these transactions on September 27, 2005.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that the GSK Trust is a discretionary trust where all employees or former employees are potential beneficiaries. Three directors (Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop) hold interests in the shares held by the GSK Trust in the same capacity as other employees. The notification complies with Disclosure Rule 3.1.4R(1)(b).
Investor Verification Checklist
- Verify the total number of shares transferred (32,688) and the date of transfer (September 26, 2005).
- Confirm the identity of the trustee (Abacus (GSK) Trustees Limited) and the specific plan involved (SmithKline Beecham Employee Share Option Plan 1991).
- Review the status of the three directors mentioned (Dr J-P Garnier, Dr T Yamada, Mr J S Heslop) regarding their interest in the GSK Trust.
- Note that this filing does not contain financial performance data for the period.